Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
Serge Goldman1, Dominique Bron2, Thomas Tousseyn3, Irina Vierasu1, Laurent Dewispelaere4, Pierre Heimann4, Elie Cogan5 and Michel Goldman6*
1Department of Nuclear Medicine, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
2Department of Hematology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
3Department of Pathology, UZ Leuven Hospitals, Leuven, Belgium
4Laboratory of Hematology, LHUB, Université Libre de Bruxelles, Brussels, Belgium
5Department of Internal Medicine, CHIREC Hospital, Brussels, Belgium
6I3h Institute, Université Libre de Bruxelles, Brussels, Belgium
Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.
Conclusion
This observation, which has been posted as a pre-print on the SSRN platform (18), suggests that vaccination with the BNT162b2 mRNA vaccine might induce rapid progression of AITL. Dedicated studies are needed to determine whether this case can be extrapolated to populations of patients with AITL or other peripheral T cell lymphoma involving TFH cells.